| (Values in U.S. Thousands) | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 |
| Sales | 1,110 | 670 | 0 | 0 | 0 |
| Sales Growth | +65.67% | unch | unch | unch | unch |
| Net Income | -8,840 | -1,520 | -31,680 | -20,960 | -22,800 |
| Net Income Growth | -481.58% | +95.20% | -51.15% | +8.07% | -28.09% |
Gamida Cell Ltd (GMDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Gamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel.